Drug Trial Radar · NCT00540787
A Comparison of Antiarrhythmic Drug Therapy and Radio Frequency Catheter Ablation in Patients With Paroxysmal Atrial Fibrillation
Last checked: Nov 20, 2026Latest source record: Feb 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
112
Actual
Start
Aug 1, 2003
Primary completion
Jun 1, 2006
Study completion Jun 1, 2006
Sponsor
- Lead sponsor
- Biosense Webster, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 8, 2007
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Other
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare radiofrequency catheter ablation and antiarrhythmic drug treatment for the maintenance of sinus rhythm in paroxysmal atrial fibrillation patients.
Conditions
- Paroxysmal Atrial Fibrillation
Interventions
Radiofrequency ablation, antiarrhythmic drugsDevice
Patients receive either treatment.
Amiodarone, flecainide, propafenone, quinidine, dofetilide, sotalol, cibenzoline, beta blocking and calcium channel blocking agents and antiarrhythmic drugsDrug
Amiodarone will be taken at 600 mg per day for 21 days (as a loading dose) followed by 1.4g per week or 200mg per day. The daily dose may be increased to 300mg or 2.1g per week.
ThermoCool Radiofrequency CatheterDevice
Patient is ablated once, repeat ablation if paroxysmal atrial fibrillation reoccurs.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recurrence of Atrial FibrillationTime frame: One year
Locations
6 sites in 3 countries. Site status is shown where the registry gives one.
University of Alabama, Birmingham
Birmingham, Alabama
Massachusetts General Hospital
Boston, Massachusetts
Mid-Ohio Cardiology
Columbus, Ohio
Hopital Lariboisiere
Paris, France
Hôpital Haut Lèvêque
Pessac, Paris, France
Hopital Cantonal de Geneve
Geneva, Switzerland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.